Comparison of self-collected vaginal swabs and first-void urine for detection of human papillomavirus in sexually active girls and women in three South Asian countries Authors: Nigus Telele, Nishan Katuwal, Furqan Kabir, Sezanur Rahman, Sabin Bikram Shahi, Raja Ram Yadav, Fatima Aziz, Md Abir Hossain, Alexandra M Hill, Indriana Permatasari, Yubin Lee, Haeun Cho, Jiyoung Lee, Young Ae You, Hyeon Seon Ahn, Soim Park, Dipesh Tamrakar, Aneela Pasha, Anadil Alam, Farah Naz Rahman, Shafayatul Shiblee, Muslima Ejaz, M Imran Nisar, Troy D Querec, Bolarinde J Lawal, Edward M Choi, Deborah Watson-Jones, Pritha Basnet, Surendra Uranw, Rajeev Shrestha, Abha Shrestha, Fyezah Jehan, Quamrun Nahar, Aneeta Hotwani, Mustafizur Rahman, Julia A Lynch, Elizabeth R Unger, Ramokone Lisbeth Lebelo, Ramokone Lebelo, Ramokone Lebelo Published: 2026 ABSTRACT AbstractBackgroundAs more countries plan and launch human papillomavirus (HPV) vaccination campaigns, a variety of self-sampling methods and assays have been used for detecting high-risk HPV (HR-HPV) types. This study compared HR-HPV detection in self-collected vaginal swabs (SCVS) and first-void urine (FVU) among sexually active girls and women aged 15–25 years in diverse settings (Bangladesh, Nepal, and Pakistan) using harmonized methods for each step.MethodsWithin the Global Burden Estimation of HPV (GLOBE-HPV) project, which aims to estimate HPV prevalence and incidence across eight low- and middle-income countries in South Asia and Sub-Saharan Africa, we analyzed paired SCVS and FVU samples from 753 participants in Bangladesh, Pakistan, and Nepal using standardized protocols. DNA was extracted using the QIAamp DNA Mini Kit, and HPV testing was performed with the Allplex HPV28 Detection PCR assay. We evaluated HPV detection and type-specific concordance using Cohen’s Kappa, McNemar’s test, and a 3 × 3 agreement table, along with accuracy and positive/negative agreement metrics.ResultsThe overall prevalence of 14 HR-HPV types was 8.6% in SCVS and 7.2% in FVU samples. Detection rates for 7 HR-HPV vaccine types were similar (5.3% in SCVS versus 5.0% in FVU), with nearly identical HPV 16/18 rates (2.3% in SCVS and 2.4% in FVU). Bi-directional type-specific discordance was noted, with each sample type detecting unique types. SCVS demonstrated higher sensitivity for detecting HPV types beyond the 9 vaccine types with McNemar p-values of 0.013 and <0.001 for 14 and 28 types, respectively, while overall concordance remained high (Kappa >0.7). Samples with lower viral load (indicated by higher real-time PCR cycle threshold values) were more likely to yield discordant results.ConclusionSCVS and FVU yielded similar HR-HPV results, including those targeted by the 9-valent HPV vaccine, in sexually active young women. Both non-invasive self-sampling methods have potential for use in large-scale HPV surveillance programs in resource-limited settings. Introduction Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide, with approximately 85% of sexually active individuals acquiring it during their lifetime [1]. While most HPV infections clear naturally within two years, persistent HR-HPV infections—specifically those caused by the 14 oncogenic or high risk (HR) types, including HPV 16 and 18, which account for roughly 70% of cervical cancers—can lead to cervical, vulvar, and anal cancers [2–4]. Cervical cancer is the fourth most common cancer worldwide, with a disproportionate burden in low- and middle-income countries (LMICs), particularly in Africa and Asia [5]. There are highly effective vaccines to prevent infection and high rates of cure with early detection. However, South Asian countries, including Bangladesh, Pakistan, and Nepal, face significant challenges in reducing cervical cancer burden due to limited healthcare infrastructure, insufficient data on HPV burden, low rates of HPV screening, and limited access to vaccine [6,7]. In Nepal, cervical cancer is the most common cancer among women, whereas in Bangladesh and Pakistan, cervical cancer is the second most common cancer among women. Nepal and Bangladesh have introduced cervical cancer screening using visual inspection with acetic acid (VIA), for women aged 30–60 or 30–49 years, respectively, but coverage remains low in both countries. Nepal introduced HPV vaccines into their national program targeting girls 10–15 years of age in February 2025 [8], Bangladesh introduced HPV vaccination targeting girls 10–14 years of age in October 2023 [9] and Pakistan launched its first its first vaccine campaign beginning September 2025, with plans to integrate it into routine immunization thereafter [10–12]. Due to the slow progression from infection to development of cervical cancer, it may take decades to measure the impact of HPV vaccination programs on cancer reduction. Therefore, sampling tools that enable HPV DNA detection are valuable for monitoring program effectiveness over shorter periods. Self-collection methods, such as vaginal swabs and first-void urine (FVU) samples, are gaining attention as alternatives to healthcare providers-collected samples and are suitable for population-based surveillance [13,14]. Studies have shown that self-collected samples can reliably detect HR-HPV types, offering a more accessible and less invasive option [15–18]. They are especially valuable for their ease of use, privacy, and ability to reach underserved populations [19]. Self-collected vaginal swabs (SCVS) show high concordance with clinician-collected cervical swab samples for HPV detection [20]. First-void urine, with its ease of collection and non-invasive nature is another option for self-sampling [13,21–26]. In some cultures, FVU sampling may be preferred over cervical or vaginal sampling [13,14,25]. Devices like Colli-Pee® help standardize FVU collection, ensuring consistent and reliable results [25,27,28]. However, the concordance between self-collected vaginal swabs and first-void urine self-sampling is dependent on specifics of sample processing, extraction, and assays. Verification of collection methods, processing, and testing is required to assess the comparability between samples and their suitability for population-based surveillance. We aimed to compare the effectiveness of SCVS and FVU for detecting HR-HPV from sexually active girls and women aged 15–25 years in three South Asian countries as part of a larger multi-country epidemiologic study. Materials and methods Study design The Global Burden Estimation of HPV (GLOBE-HPV) study is a multi-country, multi-site project aimed at estimating the burden of HPV among girls and women in 8 GAVI-eligible countries in South Asia (Bangladesh, Pakistan, and Nepal) and sub-Saharan Africa (Democratic Republic of Congo, Ghana, Sierra Leone, Tanzania, and Zambia). One of its particular aims is to assess the incidence of persistent HPV infection through longitudinal cohort studies among sexually active girls and young women [29]. A secondary aim is to evaluate the concordance of HPV detection in paired SCVS and FVU samples collected during the baseline visit of the longitudinal cohorts to determine if data throughout study could be compared independent of sampling method. Sample size of each cohort was based on primary aims of the GLOBE-HPV study, This paper reports the results of HPV prevalence and concordance between the two self-sampling methods from the three South Asian countries participating in the GLOBE-HPV study. This study is registered on clinicaltrials.gov [30]. Study setting and period This concordance study was conducted in low-income urban and peri-urban communities across Bangladesh, Pakistan, and Nepal. Study participant recruitment in Bangladesh ran from 27 November 2023–23 May 2024 (after/during HPV vaccine rollout); in Pakistan, from 22 April to 22 July 2024 (before HPV vaccine rollout); and in Nepal, from 6 March to 10 June 2024 (before HPV vaccine rollout). Sample testing was finalized in September 2024. The participating institutions, study sites, and study population are summarized in Table 1. Table 1Study sites, study population, and sample size by country.CountryPartner InstituteTarget PopulationSample SizeTarget AgeDescription on Study SettingBangladeshicddr,baUrban low-socio-economic setting250Ever-married women up to 25 years oldUrban low-socioeconomic community located in Bauniabadh moholla at the northern part of DhakaPakistanAKUbPeri-Urban community with ongoing health and demographics surveillance253Married women 18–25 years oldFour peri-urban areas in Karachi, with an established demographic surveillance system set up by the AKU; eligible participants are followed up by 4 community-based clinics.NepalBPKIHSc and DHKUHdUrban and Rural Community250(125 at each site)Sexually active women 18–25 years oldEligible participant enrollment was carried out by BPKIHS in Dharan and by DHKUH in Dhulikhel in nearby demographically well-defined communitiesa. icddr,b: International Centre for Diarrhoeal Disease Research, Bangladesh.b. AKU: Aga Khan University, Pakistan.c. BPKIHS: B.P. Koirala Institute of Health Sciences, Nepal.d. DHKUH: Dhulikhel Hospital, Kathmandu University Hospital, Nepal. Study sites, study population, and sample size by country. a. icddr,b: International Centre for Diarrhoeal Disease Research, Bangladesh. b. AKU: Aga Khan University, Pakistan. c. BPKIHS: B.P. Koirala Institute of Health Sciences, Nepal. d. DHKUH: Dhulikhel Hospital, Kathmandu University Hospital, Nepal. The target sample size was set at 247 participants per country, accounting for an anticipated dropout rate of approximately 1%, resulting in an initial enrollment target of 250 participants per country. Assuming a sensitivity of ≥80%, specificity of ≥95%, and an HPV prevalence of approximately 8%, the expected overall agreement would exceed 90%. Under these assumptions, the anticipated Cohen’s kappa would be ≥ 0.61. In Bangladesh, the study was conducted in Bauniabadh, Mirpur, Dhaka, a densely populated (50,000 people/km²), low-socioeconomic community with limited healthcare access. The study enrolled 250 ever-married women (≤25 years old) through stratified systematic sampling. In Pakistan, 253 participants were recruited from four peri-urban coastal slum communities in Karachi including Rehri Goth, Bhains Colony, Ibrahim Hyderi, and Ali Akber Shah, which have a combined population of approximately 350,000. Enrollment was based on established line listings from a demographic surveillance system (DSS) with recruitment at the household level. In Nepal, 250 participants were selected from urban and rural catchment areas of BPKIHS and DHKUH, with recruitment conducted among women attending well-baby/ immunization clinics and through community networks facilitated by female community health volunteers using purposive sampling. Inclusion and exclusion criteria Girls and women were deemed eligible if they met the following criteria: aged within the target range, sexually active, residents of the study community for at least the past 3 months, and able to understand the purpose of the study and study procedures. When eligible for the longitudinal cohort girls/women provided informed consent or assent to provide samples every 6 months over the course of 2 years. In Bangladesh, participants were required to be currently or previously married and aged 25 years or younger (in practice, some married girls enrolled were as young as age 15 years), and in Pakistan, participants were required to be married and aged 18–25 years. In both countries, marital status was used as a proxy for sexual activity due to cultural and legal reasons. In Nepal, women aged 18–25 years were eligible if they were sexually active, regardless of marital status. The exclusion criteria included refusal to participate in any aspect of the study or the presence of a medical condition or other factor that, in the opinion of the investigator, precluded study participation. Sample collection and test procedure This sub-study was conducted under a harmonized sampling and laboratory protocol to ensure comparability of results from participating countries. Data collectors trained participants in self-collection of SCVS and FVU samples in the local languages through detailed verbal explanations, diagrams, and demonstrations and aided, if requested, to ensure proper placement of devices. [A copy of instructions to participants is provided in supplemental materials, S1 File and S2 File.] The order of sample collection was not specified. The SCVS samples were collected using the Aptima® Multitest Swab Specimen Collection Kit. The FVU samples were collected following the manufacturer’s instructions using a 10- mL Colli-Pee® device with 3.4 mL of urine conservation medium (UCM). First-void urine samples could be collected at any time of the day. Participants who had urinated within the previous hour were instructed to wait one hour before collection. For women who were menstruating on the day of their scheduled visit, the sample collection was typically rescheduled to avoid any potential effect of blood in HPV testing. A total of 753 paired SCVS and FVU samples were collected, 250 from Bangladesh, 253 from Pakistan, and 250 from Nepal (Table 1). Once collection was completed, samples were stored in cool boxes (2–8°C) and transported to the central laboratory in each country with continuous temperature monitoring to ensure stability. At the respective central laboratories (icddr,b in Bangladesh, IDRL-AKU in Pakistan, and DHKUH in Nepal), samples were accessioned and checked for quality, noting any abnormalities (e.g., missing samples, reduced volume, blood, leakage, etc.). SCVS samples were stored at −20°C. FVU samples were centrifuged at 500 rcf for 5 minutes, 9 mL removed, pellet resuspended in residual one mL of supernatant and divided into two 0.5-mL aliquots. The aliquot for DNA extraction was stored at −20°C, and the one for long-term storage was kept at −80°C. In Nepal, to avoid degradation from delays in processing during long distance transportation to the central testing laboratory, samples collected at BPKIHS were accessioned and processed locally before shipment to DHKUH, where DNA extraction and HPV testing were performed. DNA extraction from both sample types was performed manually using the QIAamp® DNA Mini Kit following the manufacturer’s instructions, with quality controls including water blanks in each extraction run. The AllPlex™ 28 HPV Detection PCR assay on a Bio-Rad CFX96 Dx system, detecting 28 HPV types (HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 68, 69, 70, 73, 82) was used for HPV detection and typing following the manufacturer’s instructions. Each laboratory’s testing personnel completed competency assessment based on defined HPV plasmid samples prior initiating study testing [31]. Results were analyzed using Seegene Viewer and formatted for REDCap. Assay validity was determined based on cycle threshold (Ct) values, and control samples included at each stage of the assay. For this study, samples were considered valid if at least one internal control or HPV type was detected. Samples were considered invalid if both internal controls were negative and no HPV was detected. Data entry, processing and statistical analysis All data were entered into REDCap (Research Electronic Data Capture) version 13.1.37 and analyses conducted using SAS 9.4 (Statistical Analysis System, RRID:SCR_008567, SAS Institute, Cary, NC). Continuous variables were summarized using the mean, standard deviation, median, minimum, and maximum values, while categorical variables were presented as counts and percentages, based on eligible participants with non-missing values. All statistical tests were two-sided with a significance level of 5%. HPV concordance between SCVS and FVU was evaluated across HPV categories, with emphasis on the 14 HR-HPV types (i.e., HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and particularly HPV 16/18. Concordance was classified as full (identical HPV types or both samples negative), partial (at least one but not all HPV types matched), or full discordance (no common HPV types detected). Overall concordance was assessed using a 3 × 3 table (positive, negative, inadequate), while type-specific concordance was evaluated using positive and negative agreement, overall agreement, positive concordance, Cohen’s Kappa coefficient, and the McNemar test. Ethical considerations Ethical approval was obtained from the relevant authorities in each participating country. In South Asia, approvals were secured from the Research Review and Ethical Review Committees of icddr,b (Bangladesh; protocol number: PR-23071); the Ethics Committee on Human Research of Aga Khan University (Pakistan; protocol number: 2023-9369-27297) and the National Bioethics Committee for Research (Pakistan; protocol number: NBCR-1011); and the Nepal Health Research Council (Nepal; protocol number: 619/2023). Additional ethical approvals were obtained from the Ethics Committee of the London School of Hygiene & Tropical Medicine (United Kingdom, LSHTM Ethics Ref: 29571) and the Institutional Review Board of the International Vaccine Institute (South Korea; IRB NUMBER: 2023−004) for each country-specific study. The study was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants aged 18 years and older. In Bangladesh, where legally married females under the age of 18 are recognized as adults under local law; written informed consent was obtained following local ethical and legal guidelines. Results HPV prevalence by sample type All samples collected were adequate for evaluation. The overall HPV prevalence and concordance between SCVS and FVU samples were analyzed using data from 753 participants across three South Asian countries. No inadequate test results were reported from either sample type (Table 2). For HPV 16/18, detection rates were similar between sample types: 2.3% in SCVS and 2.4% in FVU. The detection rate for the 7 HR-HPV vaccine types was 5.3% in SCVS samples and 5.0% in FVU samples. For the 9 HPV vaccine types and 14 HR-HPV types, the detection was slightly higher in SCVS samples (6.9% and 8.6%) compared to FVU samples (5.8% and 7.2%). Prevalence varied by country but showed the same pattern. Nepal had the highest detection rates. Table 2HPV prevalence from SCVS vs FVU by country and overall.HPV TypeBangladesh (N = 250)Pakistan (N = 253)Nepal (N = 250)Overall5 (N = 753)FVUn(%)SCVSn(%)FVUn(%)SCVSn(%)FVUn(%)SCVSn(%)FVUn(%)SCVSn(%) HPV 16/18 3(1.2%)2(0.8%)4(1.6%)4(1.6%)11(4.4%)11(4.4%)18(2.4%)17(2.3%) 7 HR-HPV vaccine types 1 6(2.4%)8(3.2%)9 (3.6%)8(3.2%)23(9.2%)24(9.6%)38(5.0%)40(5.3%) 9 HPV vaccine types 2 7(2.8%)12(4.8%)12(4.7%)13(5.1%)25 (10.0%)27 (10.8%)44(5.8%)52(6.9%) 14 HR-HPV types 3 10(4.0%)10(4.0%)11 (4.3%)13(5.1%)33 (13.2%)42 (16.8%)54(7.2%)65(8.6%) Any 28 HPV types 4 15(6.0%)20(8.0%)22 (8.7%)26 (10.3%)56 (22.4%)69 (27.6%)93(12.4%)115 (15.3%)1HPV 16, 18, 31, 33, 45, 52, 58 (7 HR-HPV vaccine types). Note this category only includes the 7 HR-HPV vaccine types covered by the nonavalent HPV vaccine and does not include HPV 6 and 11, which are considered low risk since they are not known to cause cancer.2HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 (9 HPV vaccine types). This category includes all 9 HPV vaccine types covered by the nonavalent HPV vaccine.3HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 (14 HR-HPV types)4HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 68, 69, 70, 73, 82 (any 28 HPV types). These are the 28 HPV types detectable by our Seegene Allplex28.5Prevalence for combined data from all three South Asian countries. HPV prevalence from SCVS vs FVU by country and overall. 1HPV 16, 18, 31, 33, 45, 52, 58 (7 HR-HPV vaccine types). Note this category only includes the 7 HR-HPV vaccine types covered by the nonavalent HPV vaccine and does not include HPV 6 and 11, which are considered low risk since they are not known to cause cancer. 2HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 (9 HPV vaccine types). This category includes all 9 HPV vaccine types covered by the nonavalent HPV vaccine. 3HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 (14 HR-HPV types) 4HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 68, 69, 70, 73, 82 (any 28 HPV types). These are the 28 HPV types detectable by our Seegene Allplex28. 5Prevalence for combined data from all three South Asian countries. HPV concordance by sample types As the pattern of sample type concordance did not show statistically significant differences between countries, aggregated results are shown (Table 3). Full concordance ranged from 99.3% (HPV 16/18) to 88.4% (28 HPV types) and full discordance ranged from 8.4% (28 HPV types) to 0.7% (HPV 16/18). Table 3Overall HPV concordance between SCVS and FVU for all three South Asian countries (N = 753).HPVTypeOverall HPV status of FVU, n (%)Overall HPV status of SCVS,n (%)Type Agreement,n (%)PositiveNegativeInadequateFull concordancePartial concordanceFull discordance HPV 16/18 Positive 15 (2.0%)3 (0.4%)0 (0.0%)748 (99.3%)0 (0.0%)5 (0.7%) Negative 2 (0.3%)733 (97.3%)0 (0.0%) 7 HR-HPV vaccine types 1 Positive 29 (3.9%)9 (1.2%)0 (0.0%)730 (96.9%)3 (0.4%)20 (2.7%) Negative 11 (1.5%)704 (93.5%)0 (0.0%) 9 HPV vaccine types 2 Positive 34 (4.5%)10 (1.3%)0 (0.0%)722 (95.9%)3 (0.4%)28 (3.7%) Negative 18 (2.4%)691 (91.8%)0 (0.0%) 14 HR-HPV types 3 Positive 41 (5.5%)13 (1.7%)0 (0.0%)709 (94.2%)7 (0.9%)37 (4.9%) Negative 24 (3.2%)675 (89.6%)0 (0.0%) Any 28 HPV types 4 Positive 73 (9.7%)20 (2.7%)0 (0.0%)669 (88.8%)21 (2.8%)63 (8.4%) Negative 42 (5.6%)618 (82.0%)0 (0.0%)1HPV 16, 18, 31, 33, 45, 52, 58 (7 HR-HPV vaccine types).2HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 (9 HPV vaccine types).3HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 (14 HR-HPV types).4HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 68, 69, 70, 73, 82 (any 28 HPV types). Overall HPV concordance between SCVS and FVU for all three South Asian countries (N = 753). 1HPV 16, 18, 31, 33, 45, 52, 58 (7 HR-HPV vaccine types). 2HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 (9 HPV vaccine types). 3HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 (14 HR-HPV types). 4HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 68, 69, 70, 73, 82 (any 28 HPV types). The overall type-specific agreement between SCVS and FVU samples for detection of each type-group was greater than 99% (range 99.5% − 99.7%), with high negative concordance (99.8%) and positive concordance ranging from 76.2% (HPV16/18) to 57.8% for 28 HPV types (Table 4). Kappa values ranged between 0.86 (HPV 16/18) to 0.73 (28 HPV types), indicating moderate to strong agreement. Significant McNemar p-values for 14 HR types and 28 HPV types indicated increased detection in SCVS. Table 4Type-specific concordance between SCVS and FVU for all three South Asian countries (N = 753).HPV16/18SCVS(+)SCVS(-)TotalProportion discrepant types, %PositiveAgreement, %(95% CI)NegativeAgreement, %(95% CI)Overall agreement,%Positive concordance,%Kappa(95% CI)Mc-Nemarp-valueFVU(+)163190.3388.9(74.4 - 100)99.8(99.6 - 100)99.776.20.86(0.74 - 0.98)0.655FVU(-)214851487Total1814881506 7 HR-HPV vaccine types 1 SCVS(+) SCVS(-) Total Proportion discrepant types, % Positive Agreement, % (95% CI) Negative Agreement, % (95% CI) Overall Agreement, % Positive concordance, % Kappa (95% CI) Mc- Nemar p-value FVU(+) 3911500.4476.5(64.8 - 88.1)99.8(99.7 - 99.9)99.662.90.77(0.68 - 0.86)0.835 FVU(-) 1252095221 Total 5152205271 9 HPV vaccine types 2 SCVS(+) SCVS(-) Total Proportion discrepant types, % Positive Agreement, % (95% CI) Negative Agreement, % (95% CI) Overall Agreement, % Positive concordance, % Kappa (95% CI) Mc- Nemar p-value FVU(+) 4813610.4970.6(59.8 - 81.4)99.8(99.7 - 99.9)99.559.30.74(0.66 - 0.83)0.223 FVU(-) 2066966716 Total 6867096777 14 HR-HPV types 3 SCVS(+) SCVS(-) Total Proportion discrepant types, % Positive Agreement, % (95% CI) Negative Agreement, % (95% CI) Overall Agreement, % Positive concordance, % Kappa (95% CI) Mc- Nemar p-value FVU(+) 7517920.4968.2(59.5 - 76.9)99.8(99.8 - 99.9)99.559.10.74(0.67 - 0.81)0.013 FVU(-) 351041510450 Total 1101043210542 Any 28 HPV types 4 SCVS(+) SCVS(-) Total Proportion discrepant types, % Positive Agreement, % (95% CI) Negative Agreement, % (95% CI) Overall Agreement, % Positive concordance, % Kappa (95% CI) Mc- Nemar p-value FVU(+) 144321760.5066.4(60.1 - 72.6)99.8(99.8 - 99.9)99.557.80.73(0.68 - 0.78)<0.001 FVU(-) 732083520908 Total 2172086721084[Note] 2x2 table is developed by summing the cases for each HPV type within the HPV-type group. Proportion discrepant types: Total number of discordant cases / Total. Positive agreement: Total number of positives detected by both SCVS and FVU / Total number of positives detected by SCVS. Negative agreement: Total number of negatives detected by both SCVS and FVU / Total number of negatives detected by SCVS. Overall agreement: Total number of positives and negatives by both FVU and SCVS / Total. Positive concordance: Total number of positives detected by both SCVS and FVU / Total number of positives detected by SCVS or FVU.17 HR-HPV vaccine types: HPV 16, 18, 31, 33, 45, 52, 58; 2 9 HPV vaccine types: HPV 6, 11, 16, 18, 31, 33, 45, 52, 58; 3 14 HR-HPV types: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68; 4 Any 28 HPV types: HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 68, 69, 70, 73, 82. Type-specific concordance between SCVS and FVU for all three South Asian countries (N = 753). [Note] 2x2 table is developed by summing the cases for each HPV type within the HPV-type group. Proportion discrepant types: Total number of discordant cases / Total. Positive agreement: Total number of positives detected by both SCVS and FVU / Total number of positives detected by SCVS. Negative agreement: Total number of negatives detected by both SCVS and FVU / Total number of negatives detected by SCVS. Overall agreement: Total number of positives and negatives by both FVU and SCVS / Total. Positive concordance: Total number of positives detected by both SCVS and FVU / Total number of positives detected by SCVS or FVU. 17 HR-HPV vaccine types: HPV 16, 18, 31, 33, 45, 52, 58; 2 9 HPV vaccine types: HPV 6, 11, 16, 18, 31, 33, 45, 52, 58; 3 14 HR-HPV types: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68; 4 Any 28 HPV types: HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 68, 69, 70, 73, 82. Cycle threshold (Ct) value Cycle threshold (Ct) values, which inversely reflect viral copy numbers, were compared between samples that yielded concordant and discordant HPV detection between SCVS and FVU samples. Data for Bangladesh, Pakistan, and Nepal, as well as all three countries combined are shown (Fig 1, Table 5). The 274 concordant cases had a mean Ct value of 28.8 (95% CI: 28.1–29.5, range 14.7–40.6) with similar results for either sample type. The 104 discordant cases had mean Ct values of 36.1 (95% CI: 35.1–37.0, range 18.5–42.9); significantly higher than the Ct values of concordant samples (p < 0.001). Results for either sample type were similar. Results for each country analyzed separately show the same pattern (Supporting information S1 Fig, S2 Fig, and S3 Fig). Rates of concordance and discordance between SCVS and FVU according to Ct value for the three South Asian countries. Table 5Overall Ct value summary.CategoryNMean (95% CI)Median (Q1-Q3)Min-Max Concordant 274 28.8 (28.1-29.5) 28.5 (24.6-33.5) 14.7-40.6 Concordant – SCVS13727.9 (27.0-28.9)27.8 (23.8-31.6)15.3-39.5Concordant – FVU13729.6 (28.6-30.6)30.2 (25.6-35.0)14.7-40.6 Discordant 104 36.1 (35.1-37.0) 37.6 (33.6-39.3) 18.5-42.9 Discordant – SCVS7236.2 (35.2-37.2)37.5 (33.5-39.3)23.7-42.6Discordant – FVU3235.8 (33.6-38.0)37.8 (34.4-39.4)18.5-42.9[Note] For the comparison two samples t-test was used.• P-value for comparison Concordant vs. Discordant is < 0.001.• P-value for comparison Concordant -SCVS vs Discordant – SCVS is < 0.001.• P-value for comparison Concordant – FVU vs Discordant – FVU is < 0.001. Overall Ct value summary. [Note] For the comparison two samples t-test was used. • P-value for comparison Concordant vs. Discordant is < 0.001. • P-value for comparison Concordant -SCVS vs Discordant – SCVS is < 0.001. • P-value for comparison Concordant – FVU vs Discordant – FVU is < 0.001. Discussion In this study we evaluated the concordance between SCVS and FVU samples for HPV typing among sexually active girls and women from three South Asian countries: Bangladesh, Pakistan, and Nepal. Our findings provide strong evidence that both self-sampling methods provide comparable results for HPV detection, with SCVS demonstrating slightly higher sensitivity in detecting a broader range of HPV types, particularly non-vaccine HR and low risk types. These results demonstrate the use of self-sampling approaches, both FVU and SCV to assess changes in HPV genotype epidemiology and monitor vaccine impact [13,15,16]. The concordance between SCVS and FVU samples for HPV detection was similar across all study sites. The concordance for HPV 16/18 was very high, with overall agreement exceeding 99% across all study sites and Kappa values of 0.80 (95% CI: 0.75–0.85) in Bangladesh, 0.80 (95% CI: 0.76–0.84) in Pakistan, and 0.91 (95% CI: 0.88–0.94) in Nepal. For the combined data from the three countries, the concordance of HPV 16/18 detection between SCVS and FVU was also notably high, with a Kappa value of 0.86 (95% CI: 0.74–0.98). These results align with previous studies highlight strong agreement between first-void urine and cervical swab samples for detecting HPV 16/18 [13,16,32,33]. We found substantial concordance between SCVS and FVU, with Kappa values of 0.77 (95% CI: 0.68–0.86) for 7 HR-HPV vaccine types, 0.74 (95% CI: 0.66–0.83) for 9-valent types, and 0.74 (95% CI: 0.67–0.81) for 14 HR-HPV types. Positive agreement rates were 76.5% for 7 HR-HPV vaccine types, 70.6% for 9 HPV vaccine types, and 68.2% for 14 HR-HPV types, while negative agreement remained high (>99%). These findings are consistent with previous studies, which reported self-collected samples, including urine, reliably detect HR-HPV [13,26,27,34,35]. It should be noted that in settings with higher HPV prevalence, the positive agreement rates could be expected to be lower, affecting the overall agreement. Notably, while the concordance of the HR-HPV vaccine types was high, we observed a slightly lower positive agreement for the broader HPV type groups, particularly those including non-vaccine and LR-HPV types. For any of the 28 HPV types, the Kappa value was 0.73 (95% CI: 0.68–0.78), with a positive agreement of 66.4% (95% CI: 60.1–72.6) and a negative agreement of 99.8% (95% CI: 99.8–99.9), aligning with previous studies demonstrating moderate-to-high agreement of FVU with cervical samples [16,17,25]. Yang et al. reported Kappa < 0.6 for LR HPV types (44). On the other hand, other studies evaluating paired urine and cervical samples have reported slightly lower detection rates for LR-HPV types in vaginal and cervical samples than FVU collected with Colli-Pee device [27]. However, in contrast to our findings, some studies have reported that urine samples generally exhibit moderate to lower sensitivity than cervical and vaginal specimens for detecting HR-HPV types. A systematic review and meta-analysis noted that sensitivity was significantly higher when FVU samples were used compared to random or midstream urine (P = 0.004) [16]. A study using the Cobas 4800 HPV test (a clinically validated PCR-based assay) using 5–50 mL first-stream urine reported a sensitivity of 68.6% for urine samples compared to 92.3% for cervical samples, while specificity remained high at 93.2% [36]. Sample collection and processing has been shown to impact HPV detection in urine, attributable to several factors, including suboptimal timing of sample collection less than one hour after the last urination [13,28]; the use of random or midstream urine instead of FVU [16]; absence or improper use of preservatives, inadequate storage conditions [37], inefficient sample concentration and DNA extraction methods, and variability in the sensitivity and specificity of the HPV detection assays employed [36,38]. Our study also assessed Ct values, which are inversely related to viral load. concordant types had significantly lower Ct values than discordant types, suggesting that that discrepancies between SCVS and FVU detections are more likely when viral DNA concentrations are low, nearing the detection threshold of the assay. Although no previous studies have directly compared Ct values in cases of discordant HPV detection between self-collected urine and swab-based samples, Van Keer et al., reported good agreement in HPV viral load (DNA copies) between FVU samples and reference cervical samples [25]. However, Payan et al. reported HPV viral loads to be approximately 50-fold higher in cervical samples than in urine (5.00 ± 1.73 vs. 3.77 ± 1.32 log/mL; p < 0.001) [39]. Variations in reported copy numbers or Ct values can be attributed to differences in sample processing of both urine and swab (collection device, type and volume of media, extraction method). The vaginal swab, directly sampling the cervical vaginal pool, could have higher viral load, but using a large volume of sample collection media could dilute the sample. Urine collects cervical/vaginal cells indirectly, with highest concentrations in first-void. Processing can further concentrate cells through pelleting, as used in our study. The HPV assay characteristics can also affect the agreement between sample methods, as sensitive amplification assays can mitigate differences in copy numbers. A recent study evaluating the Allplex HPV28 assay demonstrated that HR-HPV detection in FVU samples is accurate regardless of whether DNA is extracted manually or automatically and does not require urine pre-centrifugation [40]. Conclusions Both SCVS and FVU samples are reliable for HPV detection, with SCVS showing slightly higher sensitivity, especially as the number of HPV types increased. Despite minor differences, FVU demonstrated high concordance with SCVS, particularly for HPV 16/18, 7 HR-HPV, and 9-vaccine types. Higher viral loads (lower Ct values) were linked to stronger SCVS-FVU concordance. Strengths and limitations A major strength of this study is its large sample set from socioeconomically similar communities in three geographically distinct countries (Bangladesh, Pakistan, and Nepal), with harmonized sample collection and testing methods, enabling robust comparisons between SCVS and FVU for HPV detection. It should be noted that results with different sampling devices, media, processing, extraction and assays could differ and neither sample method was compared to results from a clinician collected sample. The results may be helpful in planning validation of collection methods for cervical cancer screening, but this study was not designed to evaluate suitability of either sample for screening. In addition, the results reflect HPV detection in young sexually active women aged 18–25 years in the cohorts sampled, and may not be generalizable to other age groups and populations that may have higher HPV prevalences or populations evaluated for cervical disease (who may have higher viral loads). Extensive training and verification of methods were performed as part of the harmonization, however, variations between sites cannot be entirely excluded. Supporting information Participant instructions for self-collected vaginal swab. (DOCX) Participant instructions for self-collected first-void urine. (DOCX) Rate of concordance and discordance between FVU and SCVS according to Ct value for Bangladesh. (TIF) Rate of concordance and discordance between FVU and SCVS according to Ct value for Pakistan. (TIF) Rate of concordance and discordance between FVU and SCVS according to Ct value for Nepal. (TIF) Acknowledgments We would like to thank the study participants for their valuable time and cooperation. We also thank the dedication of the data collectors and field staff for their hardworking efforts throughout the data and sample collection. Data Availability De-identified individual participant data underlying the results reported in this article, generated as part of the GLOBE-HPV study, will be made available through Vivli (https://vivli.org), a controlled-access data sharing platform. The GLOBE-HPV study page can be accessed through the DOI: https://doi.org/10.25934/PR00009772. Researchers may request access to study-related data and supporting documentation relevant to this paper through the Vivli platform by submitting a formal data access request, which is subject to review and approval according to established data access procedures. Funding Statement This research was supported by Gates Foundation under Investment ID INV-046024 and Swedish Government through IVI Europe Regional Office (IERO). References 23 Mar 2026 PONE-D-25-43925 Comparison of self-collected vaginal swabs and first-void urine for detection of human papillomavirus in sexually active girls and women in three South Asian countries PLOS One Dear Dr. Telele, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== Thank you for submitting your paper to PLOS One for potential publication. This is relevant and important study in the era of cervical cancer elimination and WHO 2030 goals. Please address the comments from Reviewer 1 and 9 fully, having a response for every comment. Please also pay attention to the feedback from reviewers 2, 4, 6, 8, and 11. These are critical issues to address: 1. The novelty of the study must be made clear by the authors since this is not the first paper to report the comparison of FVU and self collected samples. 2. The study participants have different characteristics, from all three sites, please explain the rationale and how bias would be avoided. This is includes age, marital status etc. In some instances the first void urine was not collected however this is not accounted for in the analysis and the title, this may compromise the results. 3. How was consistency in sample collection and recruitment ensured throughout the three sites? ============================== Please submit your revised manuscript by May 04 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Ramokone Lisbeth Lebelo, Ph.D Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating in your Funding Statement: [This research was supported by Gates Foundation under Investment ID INV-046024 and Swedish Government through IVI Europe Regional Office (IERO)]. Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now. Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement. Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf. 3. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript. 4. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Before we proceed with your manuscript, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible. Please update your Data Availability statement in the submission form accordingly. 5. In the online submission form, you indicated that [De-identified data can be made available upon reasonable request.]. All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Additional Editor Comments: Thank you for submitting your paper to PLOS One for review. We sincerely apologize for the prolonged period of review, it is not the standard of PLOS One. The decision on your paper was based on the reviewer's comments as major comments. Please address the comments and reviews of Reviewer 1 and Reviewer 9 fully. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: Yes Reviewer #6: Yes Reviewer #7: Yes Reviewer #8: Yes Reviewer #9: Yes Reviewer #10: Yes Reviewer #11: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: Yes Reviewer #6: Yes Reviewer #7: Yes Reviewer #8: Yes Reviewer #9: Yes Reviewer #10: Yes Reviewer #11: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: No Reviewer #5: Yes Reviewer #6: Yes Reviewer #7: Yes Reviewer #8: Yes Reviewer #9: No Reviewer #10: Yes Reviewer #11: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: Yes Reviewer #6: Yes Reviewer #7: Yes Reviewer #8: Yes Reviewer #9: Yes Reviewer #10: Yes Reviewer #11: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The article entitled, “Comparison of self-collected vaginal swabs and first-void urine for detection of human papillomavirus in sexually active girls and women in three South Asian countries,” by Telele et al., describes a cross-sectional study wherein the authors compared two non-invasive sampling methods for HPV DNA detection. The authors collected 753 samples from sexually active females ages 15–25 in Bangladesh, Pakistan, and Nepal using two methods, i.e., self-collected vaginal swabs (SCVS) and first-void urine (FVU). The authors used a harmonized protocol not only to assess HPV prevalence but also to determine concordance between the two sample types. Though the study appears to be scientifically sound, and the manuscript is well organized and prepared, there are few changes required to strengthen the objectives and outcomes of the study. The manuscript can be accepted for publication in the PLoS One after replies to the following comments are addressed satisfactorily: 1. The authors cited similar studies that have compared self-collected vs urine samples for HPV. The authors should mention with clarity what is the uniqueness/novelty of the present study. 2. In the introduction section, instead of over emphasizing the HPV background and self-sampling the authors should focus on the research question and what knowledge gap is being filled by carrying out the present study. 3. The authors should provide the justification of cohort chosen especially the reason for age of 15-25 years and if / how it is related to HPV vaccination. Why do authors have not included broader age range? The reasoning behind the narrative should be provided in the manuscript as it would strengthen the manuscript. 4. The recruitment strategies detailed in the present study differed by country. Such as, the authors carried clinical based sampling in Nepal; demographic surveillance in Pakistan and sampling of married women in Bangladesh. The impact of recruitment strategy can be on the results / observations of the study. The authors should provide a clarification on the approach. 5. In discussion section, the authors could provide information on comparing the practical advantages between the two methods of sampling. They should also discuss how the present study outcomes can have influence on screening strategies. The authors can summarize the major findings/takeaways of the present study in conclusion. 6. As the samples were self-collected, the authors should acknowledge the limitations of the method because of absence of clinician / trained personnel collected samples as it can impact the outcome of the result. The authors should mention other limitations too. 7. The authors should provide the probable reasons for the observations that why Nepal had higher HPV prevalence than other two countries. Further, authors should mention if they have any plans for future studies to follow up or some other objectives. 8. The authors should ensure consistency in use of HPV-related terms. Such as at some places for High Risk ‘hr’ is used while at other places ‘HR’ is used. Authors should check the manuscript to make sure about uniformity. 9. Authors should make sure that all web references have accessed date and formatted as per PLoS One requirements. Also, make sure that all the references are cited and citations provided meet the PLoS One requirements. Reviewer #2: This is an automated report for PONE-D-25-43925. This report was solicited by the PLOS One editorial team and provided by ScreenIT. ScreenIT is an independent group of scientists developing automated tools that analyze academic papers. A set of automated tools screened your submitted manuscript and provided the report below. Each tool was created by your academic colleagues with the goal of helping authors. The tools look for factors that are important for transparency, rigor and reproducibility, and we hope that the report might help you to improve reporting in your manuscript. Within the report you will find links to more information about the items that the tools check. These links include helpful papers, websites, or videos that explain why the item is important. While our screening tools aim to improve and maintain quality standards they may, on occasion, miss nuances specific to your study type or flag something incorrectly. Each tool has limitations that are described on the ScreenIT website. The tools screen the main file for the paper; they are not able to screen supplements stored in separate files. Please note that the Academic Editor had access to these comments while making a decision on your manuscript. The Academic Editor may ask that issues flagged in this report be addressed. If you would like to provide feedback on the ScreenIT tool, please email the team at ScreenIt@bih-charite.de. If you have questions or concerns about the review process, please contact the PLOS One office at plosone@plos.org. Reviewer #3: Excellent work! This is a very important piece of research regarding Human Papilloma Virus infection in a young sexually active population. The methods used are rigorous and reproducable. They serve as the template for future work on this topic. Reviewer #4: This manuscript presents a valuable multi-country study evaluating the concordance between self-collected vaginal swabs (SCVS) and first-void urine (FVU) for HPV detection among young women in Bangladesh, Nepal, and Pakistan. The study addresses a critical public health need in resource-limited settings. The methodology is robust, the sample size is adequate, and the manuscript is well-written. The harmonized protocol across three countries is a significant strength. However, I have a few minor comments and queries that, if addressed, would further strengthen the manuscript. Specific Comments: Sample Validity: The results state (Page 12, Line 196) that "No inadequate test results were reported from either sample type." Given the nature of self-collection and the large sample size (N=753 pairs), a 0% invalid rate is exceptionally evident of high-quality supervision or robust DNA extraction methods. Could the authors briefly clarify in the Methods section if any participants were excluded prior to the final N=753 count due to sample insufficiency, or if the "UCM" buffer and extraction protocol truly yielded 100% valid DNA for all collected samples? This detail speaks to the feasibility of this method in real-world surveillance. Data Availability: The authors have indicated that data is available "upon reasonable request" due to ethical restrictions. Please ensure this complies with PLOS ONE’s strict data availability policy. If the data contains sensitive patient information that prevents public deposition, the specific ethical restrictions and the contact information for a non-author institutional body (e.g., an Ethics Committee) should be clearly stated in the final declaration, rather than just the authors' contact. Cycle Threshold (Ct) Analysis: The comparison of Ct values between concordant and discordant samples is a very insightful addition (Figure 1). It clearly demonstrates that discordance is driven by low viral loads. It would be beneficial to briefly discuss the clinical implication of this: are the "missed" infections in discordant cases likely to be clinically significant (e.g., persistent infections) or transient low-load infections? Demographics: The study population varies slightly by country (e.g., married women in Bangladesh/Pakistan vs. sexually active women in Nepal). While the authors acknowledge this in the limitations, a brief sentence in the Discussion on whether marital status (and implied sexual behavior differences) might impact the vaginal microbiome or viral load—and thus detection concordance—would be interesting, though not mandatory. Logistics: The conclusion emphasizes the potential for these methods in "resource-limited settings." However, the methods describe a cold chain (2-8^{\circ}C transport, -20^{\circ}C storage). In the Discussion, could the authors comment on the stability of samples in the UCM buffer at ambient temperature? This is crucial for true utility in remote areas without cold chain infrastructure. Conclusion: The study is technically sound and provides important data for HPV surveillance strategies in South Asia. I recommend publication after these minor points are addressed. Reviewer #5: This is a very important study for public health in South Asia. Comparing self-collected vaginal swabs and urine for HPV testing is a great idea, especially for reaching women in resource-limited settings. I really appreciate that you collected data from three different countries (Bangladesh, Nepal, and Pakistan). The results are clear and promising—showing that both methods work well for detecting high-risk HPV. This will be very helpful for future vaccination monitoring programs. I have no changes to request. Congratulations on a successful multi-country study. Reviewer #6: Introduction * Your final aim statement says “sexually active girls and women aged 15–25 years” (line 85), but your Methods section indicates 18–25 in Pakistan and Nepal and “ever-married ≤25” in Bangladesh. Ensure the aim statement aligns with the enrolled age ranges ("18–25 years” overall, or “≤25 years"), maybe with a brief note about country-specific eligibility. * You have said that “Pakistan has not yet introduced the HPV vaccine” (lines 54–55). That is no longer accurate: Pakistan launched its first HPV vaccine rollout/campaign beginning September 15, 2025, with plans to integrate it into routine immunization thereafter. * The reader will want a tighter argument for why concordance between SCVS and FVU matters in your specific context. I recommend adding 1–2 sentences on whether your primary use case is population-based surveillance, screening uptake, or post-vaccine monitoring, and why urine might be preferable in South Asia (acceptability, cultural norms, logistics, clinic capacity). * The introduction can be precise. Consider trimming 1–2 sentences on virology/classification, and use that space to sharpen the study rationale. Methodology and Results * The target populations and recruitment strategies vary (Bangladesh: “ever-married ≤25” with stratified systematic sampling; Pakistan: married 18–25; Nepal: sexually active 18–25). This affects both prevalence estimates and potentially concordance if underlying risk factors differ. Please provide baseline participant characteristics by country (age distribution, marital status, parity, education, contraceptive use, recent sexual activity, etc.) and discuss how these differences may influence outcomes. * Self-collection procedures require a little more detail, such as the order of collection and assistance/observation, FVU timing.... * The high overall agreement/negative agreement (Table 4) likely reflects low prevalence and a large proportion of negative pairs (as your negative agreement is >99%). This is expected but can overstate “equivalence.” Mention this issue in the discussion or emphasize positive concordance and directional discordance. * Table 3 text: “full discordance ranged from 8.4% (38 HPV types)” appears to be a typo; it should likely be 28 HPV types. Reviewer #7: Excellent paper and an important topic. This paper discusses an important and emerging topic. It helps inform our current knowledge and will prove beneficial for the medical community. The methodology is rigorous. Reviewer #8: Thanks for your manuscript. Comments The inclusion criteria and clinical background of the study population are not clearly defined. It is not fully explained whether participants were attending for routine screening, symptomatic evaluation, abnormal cytology follow-up, or other clinical reasons. Because the sample is hospital-based, this may introduce selection bias and limit generalizability to the broader population. The authors should clearly describe the recruitment setting and clinical indications for participation. The cross-sectional nature of the study limits causal interpretation. Some parts of the discussion imply transmission directionality or risk relationships between cervical and anal HPV infection. However, cross-sectional data cannot establish temporality or causation. The manuscript should revise the language to focus strictly on associations rather than inferred transmission pathways. Potential confounding variables are not adequately addressed. Important factors such as sexual behavior, number of sexual partners, smoking status, contraceptive use, immunosuppression, and HIV status could influence HPV prevalence. Without adjustment for these variables, observed associations may be partially confounded. If such data were not collected, this should be clearly acknowledged as a limitation. The manuscript does not clearly report whether any samples were excluded due to insufficient DNA, invalid results, or missing data. A participant flow diagram summarizing eligible, excluded, and analyzed cases would improve transparency and align with reporting standards. Reviewer #9: General comments This study compares self-collected vaginal swabs with first-void urine samples for HPV detection among sexually active girls and women in three South Asian countries. The question is both practical and relevant, particularly in settings where expanding access to cervical cancer screening remains a challenge. Overall, the study appears thoughtfully designed, and the main findings are generally supported by the data presented. A few areas, however, would benefit from additional clarification to improve transparency and reporting. Major Comments 1. Study Design and Recruitment It would be helpful to provide more detail about how participants were recruited (e.g., consecutive vs convenience sampling) and to clarify the inclusion and exclusion criteria more explicitly. Please also indicate whether HPV vaccination status was recorded and considered in the analysis. In addition, clarifying whether the order of sample collection (swab vs urine) was standardized would help readers assess potential procedural effects. 2. Laboratory Procedures Additional detail regarding the HPV assay would improve reproducibility, including its validation status, limit of detection, and any internal quality controls used. Please also clarify whether laboratory personnel were blinded to specimen type and whether quality assurance procedures were consistent across the participating countries. 3.Statistical Methods The statistical analysis would benefit from clearer reporting. Please specify whether a sample size or power calculation was performed. Confidence intervals should be consistently reported for measures such as sensitivity, specificity, and agreement statistics. If not already included, stratified analyses by country or age group could help explore potential variability across sites. 4.Interpretation of Findings The conclusions are generally supported by the results; however, where equivalence between sample types is implied, the language may need to be slightly moderated unless a predefined non-inferiority framework was applied. Expanding briefly on possible reasons for discordant results between specimen types would also strengthen the discussion. 5. Data Availability The Data Availability Statement indicates that data are available upon reasonable request. Given PLOS ONE’s data-sharing policy, please clarify whether the dataset can be deposited in a public repository or provide a more detailed explanation of any restrictions that prevent open access. Minor Comments The manuscript is generally well written and clear, with only minor language refinements needed. Please ensure consistent terminology (e.g., “first-void urine” throughout). Tables should clearly specify denominators when percentages are reported. Overall, this is an important and relevant study. With the clarifications above, the manuscript would be strengthened and better aligned with reporting standards. Reviewer #10: The manuscript is well structured, all of the data was provided, statistical analysis was performed appropriately. the manuscript and data was supporting the conclusion and all of the required details were shared. Reviewer #11: General Comments: - This manuscript reports original, multicountry research comparing self-collected vaginal swabs (SCVS) and first-void urine (FVU) for HPV detection among young women in South Asia. The study addresses an important public health question in low- and middle-income countries and contributes valuable evidence for HPV surveillance and screening strategies. - Minor language editing could further enhance readability. Abstract - The abstract is well structured and clearly summarizes the background, objectives, methods, key findings, and conclusions. The study design, sample size, laboratory methods, and main statistical approaches are appropriately described. The results are presented quantitatively and support the stated conclusions. The abstract accurately reflects the content of the manuscript and meets PLOS ONE standards for clarity and completeness Introduction - Provides a comprehensive overview of HPV epidemiology, cervical cancer burden, and screening challenges in South Asia. The authors effectively contextualize the need for self-sampling approaches and cite relevant international and regional literature. The rationale for comparing SCVS and FVU is well justified, and the research objectives are clearly stated. - Lines 44–60 in the Introduction contain detailed country-specific descriptions of cervical cancer burden in Bangladesh, Pakistan, and Nepal. While this information is relevant, this section could be streamlined to improve conciseness and flow. Given that the study focuses on three countries, the authors may consider briefly explaining the rationale for selecting these specific settings (e.g., representativeness, programmatic relevance, epidemiological burden, or participation in the GLOBE-HPV project). In addition, the epidemiological background could be summarized more succinctly by presenting key indicators—such as HPV prevalence, cervical cancer incidence, and mortality rates—for each country, rather than providing extended narrative descriptions. Condensing this section would enhance readability while maintaining its contextual value, and would allow readers to more quickly understand the public health relevance of the selected study sites. Materials and Methods The manuscript states that in Bangladesh and Pakistan, participants were required to be married, whereas in Nepal eligibility was based on being sexually active regardless of marital status. Could the authors please clarify the rationale for this difference in inclusion criteria across countries? Specifically: - Was marital status used as a proxy for sexual activity in Bangladesh and Pakistan due to sociocultural or ethical considerations? - Were there regulatory or institutional constraints that prevented recruitment of unmarried sexually active women in those settings? - How might this difference affect comparability of HPV prevalence and concordance estimates across the three countries? A brief explanation in the Methods section, and possibly a note in the Limitations section addressing potential selection bias or differences in sexual behavior patterns, would strengthen transparency and interpretation of cross-country comparisons. Sample Size Could the authors please clarify: - Whether a formal sample size or power calculation was performed for this concordance analysis? - If so, which assumptions were used (expected HPV prevalence, anticipated agreement/Kappa value, precision, alpha level)? - Whether the target of approximately 250 participants per country was based on logistical considerations, cohort design, or statistical requirements of the GLOBE-HPV project? Results - The manuscript reports no inadequate test results; however, additional clarification on data completeness (e.g., missing demographic or behavioral variables) would improve transparency. - The description of discordant cases could be expanded, for example by indicating whether discordance was more frequent in specific subgroups (country, age range, or HPV type categories). Discussion The Discussion section is generally well written and provides an appropriate interpretation of the study findings in relation to existing literature. The authors successfully contextualize their results within prior studies on self-sampling for HPV detection and highlight the relevance for surveillance in low- and middle-income settings. However, several aspects could be strengthened: - Balance between interpretation and speculation Some explanations regarding differences in sensitivity and concordance between SCVS and FVU appear speculative and would benefit from stronger empirical support or clearer citation of supporting evidence. - Cross-country comparability Given the differences in inclusion criteria and recruitment strategies across countries, the authors should more explicitly discuss how these variations may influence the comparability of findings and interpretation of pooled analyses. - Public health and implementation implications While the potential use of SCVS and FVU in surveillance programs is mentioned, further discussion on operational feasibility, cost considerations, and integration into existing screening systems in South Asia would enhance the practical relevance of the findings. - Limitations and potential biases The limitations section could be expanded to more clearly address potential selection bias, reporting bias related to self-sampling, and variability in laboratory processing across sites. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: Yes: Muhammad Saqib Reviewer #4: Yes: Hussein Mussa Muafa Reviewer #5: Yes: Ganesh Praneeth Roy Avula Reviewer #6: No Reviewer #7: Yes: Muhammad Saqib Reviewer #8: No Reviewer #9: No Reviewer #10: Yes: Reenam Mushtaq Reviewer #11: Yes: Jessica Marsigit ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. Submitted filename: Comments PLoS One.docx Submitted filename: report_10.1101+2025.08.01.25332560.pdf Submitted filename: General Comments.docx 29 Apr 2026 Authors’ response to reviewers' comments: Reviewer #1 The article entitled, “Comparison of self-collected vaginal swabs and first-void urine for detection of human papillomavirus in sexually active girls and women in three South Asian countries,” by Telele et al., describes a cross-sectional study wherein the authors compared two non-invasive sampling methods for HPV DNA detection. The authors collected 753 samples from sexually active females ages 15–25 in Bangladesh, Pakistan, and Nepal using two methods, i.e., self-collected vaginal swabs (SCVS) and first-void urine (FVU). The authors used a harmonized protocol not only to assess HPV prevalence but also to determine concordance between the two sample types. Though the study appears to be scientifically sound, and the manuscript is well organized and prepared, there are few changes required to strengthen the objectives and outcomes of the study. The manuscript can be accepted for publication in the PLoS One after replies to the following comments are addressed satisfactorily: 1. The authors cited similar studies that have compared self-collected vs urine samples for HPV. The authors should mention with clarity what is the uniqueness/novelty of the present study. Response: While self-collected swabs and urine samples have been studied as methods for HPV detection, the methods used, including collection devices, preservatives, processing, extraction and assays all differ. Our results add to options that have been evaluated and include the ability to perform the collection and testing in a harmonized manner. Further, we included an exploration of the impact of viral load on the concordance between samples. We modified the introduction to clarify this (page 6, lines 98 – 101). 2. In the introduction section, instead of over emphasizing the HPV background and self-sampling the authors should focus on the research question and what knowledge gap is being filled by carrying out the present study. Response: The introduction has been extensively modified to emphasize the knowledge gap being addressed. 3. The authors should provide the justification of cohort chosen especially the reason for age of 15-25 years and if / how it is related to HPV vaccination. Why do authors have not included broader age range? The reasoning behind the narrative should be provided in the manuscript as it would strengthen the manuscript. Response: The cohorts were formed based on the aims of the GLOBE-HPV study. The age group for the comparison of sampling methods was selected primarily because of the likelihood of HPV acquisition. In addition, this age group is generally considered for “catch-up” vaccination, so providing an indication of exposure to vaccine types could be of importance to countries planning HPV vaccine campaigns. 4. The recruitment strategies detailed in the present study differed by country. Such as, the authors carried clinical based sampling in Nepal; demographic surveillance in Pakistan and sampling of married women in Bangladesh. The impact of recruitment strategy can be on the results / observations of the study. The authors should provide a clarification on the approach. Response: Marital status was used as a proxy for sexual activity in Bangladesh and Pakistan due to sociocultural, religious, or ethical considerations. Asking about sexual activity outside of marriage is culturally sensitive and could cause repercussions for the participants. This explanation has been added. We do not think that this difference in recruitment impacts study findings as the cultures of Bangladesh and Pakistan result in near concordance between sexually active women and married women (page 9, lines 153 -156). 5. In discussion section, the authors could provide information on comparing the practical advantages between the two methods of sampling. They should also discuss how the present study outcomes can have influence on screening strategies. The authors can summarize the major findings/takeaways of the present study in conclusion. Response: The major takeaway of the present study is included in the conclusion, that is, both sampling methods give similar HR-HPV results. We did not collect data on practical advantages between the two methods. These would include preference of the women (not addressed), costs of materials and disposal (different in each setting due to local importing suppliers and tariffs), and laboratory facilities (standardized and key assay instrument provided as part of GLOBE-HPV). 6. As the samples were self-collected, the authors should acknowledge the limitations of the method because of absence of clinician / trained personnel collected samples as it can impact the outcome of the result. The authors should mention other limitations too. Response: The biggest limitation to the findings is that they apply to the specific sample collection tools, media, processing, extraction and assays used in this study and may not be generalizable to all methods. Lack of clinician collected samples as comparator was added to the limitations and the potential impact of population-specific factors and laboratory variations was added (page 20, lines 364 – 374). 7. The authors should provide the probable reasons for the observations that why Nepal had higher HPV prevalence than other two countries. Further, authors should mention if they have any plans for future studies to follow up or some other objectives. Response: This study is focused on comparability of sampling methods. Discussion of country-specific differences in HPV prevalence as well as persistence will be addressed in the GLOBE-HPV publications. 8. The authors should ensure consistency in use of HPV-related terms. Such as at some places for High Risk ‘hr’ is used while at other places ‘HR’ is used. Authors should check the manuscript to make sure about uniformity. Response: Checked. 9. Authors should make sure that all web references have accessed date and formatted as per PLoS One requirements. Also, make sure that all the references are cited and citations provided meet the PLoS One requirements. Response: Checked Reviewer #4: This manuscript presents a valuable multi-country study evaluating the concordance between self-collected vaginal swabs (SCVS) and first-void urine (FVU) for HPV detection among young women in Bangladesh, Nepal, and Pakistan. The study addresses a critical public health need in resource-limited settings. The methodology is robust, the sample size is adequate, and the manuscript is well-written. The harmonized protocol across three countries is a significant strength. However, I have a few minor comments and queries that, if addressed, would further strengthen the manuscript. Specific Comments: Sample Validity: The results state (Page 12, Line 196) that "No inadequate test results were reported from either sample type." Given the nature of self-collection and the large sample size (N=753 pairs), a 0% invalid rate is exceptionally evident of high-quality supervision or robust DNA extraction methods. Could the authors briefly clarify in the Methods section if any participants were excluded prior to the final N=753 count due to sample insufficiency, or if the "UCM" buffer and extraction protocol truly yielded 100% valid DNA for all collected samples? This detail speaks to the feasibility of this method in real-world surveillance. Response: None of the samples were inadequate in this set of samples, although this has been encountered in the larger study. This information has been added to the results (page 13, lines 227). Data Availability: The authors have indicated that data is available "upon reasonable request" due to ethical restrictions. Please ensure this complies with PLOS ONE’s strict data availability policy. If the data contains sensitive patient information that prevents public deposition, the specific ethical restrictions and the contact information for a non-author institutional body (e.g., an Ethics Committee) should be clearly stated in the final declaration, rather than just the authors' contact. Response: De-identified individual participant data underlying the results reported in this article will be made available through Vivli (vivli.org), where access requires submission and approval of a formal data access request. This information has been added (page 1, lines 31-33). Cycle Threshold (Ct) Analysis: The comparison of Ct values between concordant and discordant samples is a very insightful addition (Figure 1). It clearly demonstrates that discordance is driven by low viral loads. It would be beneficial to briefly discuss the clinical implication of this: are the "missed" infections in discordant cases likely to be clinically significant (e.g., persistent infections) or transient low-load infections? Response: We do not have data to address the clinical significance of low viral load infections. While it is tempting to speculate that these are less likely to persist and progress, the study was not designed to address this question. Demographics: The study population varies slightly by country (e.g., married women in Bangladesh/Pakistan vs. sexually active women in Nepal). While the authors acknowledge this in the limitations, a brief sentence in the Discussion on whether marital status (and implied sexual behavior differences) might impact the vaginal microbiome or viral load—and thus detection concordance—would be interesting, though not mandatory. Response: These cohorts were intended to represent sexually active women, however asking about sexual activity outside of marriage in Bangladesh and Pakistan was not permissible due to sociocultural, religious, or ethical considerations. Marriage was used as a proxy for sexual activity. We do not think that this difference in recruitment impacts study findings as the cultures of Bangladesh and Pakistan result in near concordance between sexually active women and married women. The concordance findings between countries was not statistically significant. We cannot comment on potential impact of many variables (e.g. genital hygiene, douching, sexual history) that may impact HPV and vaginal microbiome. Logistics: The conclusion emphasizes the potential for these methods in "resource-limited settings." However, the methods describe a cold chain (2-8^{\circ}C transport, -20^{\circ}C storage). In the Discussion, could the authors comment on the stability of samples in the UCM buffer at ambient temperature? This is crucial for true utility in remote areas without cold chain infrastructure. Response: We did not include details about the cold chain, but this was achieved in remote areas with the use of cold packs. The manufacturer of the Colli-Pee device with preservative does indicate samples are stable at ambient temperature up to 7 days, however, as ambient temperatures could differ significantly between sites, we opted to provide consistency through the use of ice packs. Further work would be necessary to verify the time of stability of samples kept at ambient temperatures. Conclusion: The study is technically sound and provides important data for HPV surveillance strategies in South Asia. I recommend publication after these minor points are addressed. Reviewer #6: Introduction * Your final aim statement says “sexually active girls and women aged 15–25 years” (line 85), but your Methods section indicates 18–25 in Pakistan and Nepal and “ever-married ≤25” in Bangladesh. Ensure the aim statement aligns with the enrolled age ranges ("18–25 years” overall, or “≤25 years"), maybe with a brief note about country-specific eligibility. Response: In Bangladesh early age at marriage is a common practice, so married girls age 15 and older were included. The overall aim statement was intended to cover all three countries, with country-specific inclusion information provided in the methods. * You have said that “Pakistan has not yet introduced the HPV vaccine” (lines 54–55). That is no longer accurate: Pakistan launched its first HPV vaccine rollout/campaign beginning September 15, 2025, with plans to integrate it into routine immunization thereafter. Response: Thank you, we have added this good news to the introduction (page 5, lines 56-57). * The reader will want a tighter argument for why concordance between SCVS and FVU matters in your specific context. I recommend adding 1–2 sentences on whether your primary use case is population-based surveillance, screening uptake, or post-vaccine monitoring, and why urine might be preferable in South Asia (acceptability, cultural norms, logistics, clinic capacity). Response: We have revised the introduction and methods to clarify that this comparison was performed in the context of the GLOBE-HPV study, an epidemiologic study of HPV in multiple countries. The introduction states that urine sampling may be preferred over cervical or vaginal sampling in some cultures (page 6, lines 83-85). * The introduction can be precise. Consider trimming 1–2 sentences on virology/classification, and use that space to sharpen the study rationale. Response: The introduction has been sharpened and rationale clarified. Methodology and Results * The target populations and recruitment strategies vary (Bangladesh: “ever-married ≤25” with stratified systematic sampling; Pakistan: married 18–25; Nepal: sexually active 18–25). This affects both prevalence estimates and potentially concordance if underlying risk factors differ. Please provide baseline participant characteristics by country (age distribution, marital status, parity, education, contraceptive use, recent sexual activity, etc.) and discuss how these differences may influence outcomes. Response: The data on participant characteristics and behaviors and their impact on HPV infection will be presented in subsequent GLOBE-HPV publications. The purpose of this analysis was to simply evaluate comparability of HPV detection by two sampling methods. As the concordance was high and similar across multiple settings, the information provides assurance that differences in epidemiologic characteristics and behaviors in these populations was not significant. * Self-collection procedures require a little more detail, such as the order of collection and assistance/observation, FVU timing.... Response: We have added the instructions for sample collection given to participants to the supplemental materials. The order of sample collection was not specified, and this information is added to the methods (page 10, lines 166-167). * The high overall agreement/negative agreement (Table 4) likely reflects low prevalence and a large proportion of negative pairs (as your negative agreement is >99%). This is expected but can overstate “equivalence.” Mention this issue in the discussion or emphasize positive concordance and directional discordance. Response: It is correct that the negative agreement in low prevalence settings contributes to the high observed concordance. The data in Table 4 also show the lower positive concordance. This is a commonly used approach to compare qualitative (i.e. positive/negative) results between two methods. A statement has been added to the discussion to note this -- It should be noted that in settings with higher HPV prevalence, the positive agreement rates could be expected to be lower, affecting the overall agreement. (page 18, lines 309-310) * Table 3 text: “full discordance ranged from 8.4% (38 HPV types)” appears to be a typo; it should likely be 28 HPV types. Response: Yes, the text should read “full discordance ranged from 8.4% (28 types) to 0.7% (HPV 16/18)” but we corrected the typo (page 14, lines 248). Reviewer #8 The inclusion criteria and clinical background of the study population are not clearly defined. It is not fully explained whether participants were attending for routine screening, symptomatic evaluation, abnormal cytology follow-up, or other clinical reasons. Because the sample is hospital-based, this may introduce selection bias and limit generalizability to the broader population. The authors should clearly describe the recruitment setting and clinical indications for participation. Response: The study setting and rationale has been clarified in the introduction and study description. Submitted filename: Response to Reviewers.docx 7 May 2026 Comparison of self-collected vaginal swabs and first-void urine for detection of human papillomavirus in sexually active girls and women in three South Asian countries PONE-D-25-43925R1 Dear Dr. Telele We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Ramokone Lisbeth Lebelo, Ph.D Academic Editor PLOS One PONE-D-25-43925R1 PLOS One Dear Dr. Telele, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Ramokone Lisbeth Lebelo Academic Editor PLOS One Supplementary Materials Participant instructions for self-collected vaginal swab. (DOCX) Participant instructions for self-collected first-void urine. (DOCX) Rate of concordance and discordance between FVU and SCVS according to Ct value for Bangladesh. (TIF) Rate of concordance and discordance between FVU and SCVS according to Ct value for Pakistan. (TIF) Rate of concordance and discordance between FVU and SCVS according to Ct value for Nepal. (TIF) Submitted filename: Comments PLoS One.docx Submitted filename: report_10.1101+2025.08.01.25332560.pdf Submitted filename: General Comments.docx Submitted filename: Response to Reviewers.docx Data Availability Statement De-identified individual participant data underlying the results reported in this article, generated as part of the GLOBE-HPV study, will be made available through Vivli (https://vivli.org), a controlled-access data sharing platform. The GLOBE-HPV study page can be accessed through the DOI: https://doi.org/10.25934/PR00009772. Researchers may request access to study-related data and supporting documentation relevant to this paper through the Vivli platform by submitting a formal data access request, which is subject to review and approval according to established data access procedures.